Targeted Designs for Clinical Trials

Venue: Philadelphia

Location: Philadelphia, Pennsylvania, United States

Event Date/Time: Jun 19, 2007 End Date/Time: Jun 20, 2007
Abstract Submission Date: Jun 19, 2007
Report as Spam


Trial costs are spiraling as trials are getting bigger and more expensive to run. Major drug manufacturers lose millions when their drug candidates are pulled in late stage clinical trials. Meanwhile, the FDA is developing non-binding guidance papers that encourage drug companies to design and implement "adaptive designs" for clinical trials.

Pharma and Biotech companies seem to be willing to roll out trials using targeted designs because it allows them to make earlier decisions, lower drug development costs and reduce the time it takes to bring a drug to market. In fact, each of the FDA`s drug evaluation branches already report having received such trial proposals from pharmaceutical and biotech sources.

Diagnostic companies are also eager to see targeted designs in clinical trials because it bridges the gap between the pharma and diagnostics industries. Although historically these two industries have had less than a synergistic relationship, recent finanicial and regulatory concerns are pushing the two together. Pharma companies rely on diagnostic partners to discover the full potential of their drug candidates, while diagnostic companies stand to realize quicker times to market if they gain R&D support from drug manufacturers.

Join us on July 19-20, 2007 in Philadelphia, PA for "Targeted Designs for Clinical Trials". Learn from leading experts on how to accelerate the path to drug development, lower your clinical trial costs and improve your study`s therapeutic ratio of benefit to adverse effects.

Attend with your colleagues: Register 2, the 3rd goes free!